The Manufacturers Life Insurance Company Grows Holdings in Momenta Pharmaceuticals, Inc. (MNTA)

The Manufacturers Life Insurance Company raised its holdings in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 11.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 56,563 shares of the biotechnology company’s stock after purchasing an additional 5,622 shares during the period. The Manufacturers Life Insurance Company owned 0.07% of Momenta Pharmaceuticals worth $957,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the business. Tortoise Investment Management LLC acquired a new stake in shares of Momenta Pharmaceuticals in the 2nd quarter valued at approximately $114,000. Pinebridge Investments L.P. raised its position in shares of Momenta Pharmaceuticals by 4.3% in the 2nd quarter. Pinebridge Investments L.P. now owns 8,798 shares of the biotechnology company’s stock valued at $149,000 after acquiring an additional 363 shares during the period. State of Alaska Department of Revenue raised its position in shares of Momenta Pharmaceuticals by 84.6% in the 2nd quarter. State of Alaska Department of Revenue now owns 13,184 shares of the biotechnology company’s stock valued at $222,000 after acquiring an additional 6,044 shares during the period. Profund Advisors LLC raised its position in shares of Momenta Pharmaceuticals by 13.1% in the 2nd quarter. Profund Advisors LLC now owns 13,172 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 1,530 shares during the period. Finally, Citigroup Inc. raised its position in shares of Momenta Pharmaceuticals by 263.2% in the 2nd quarter. Citigroup Inc. now owns 13,736 shares of the biotechnology company’s stock valued at $232,000 after acquiring an additional 9,954 shares during the period. Institutional investors own 91.19% of the company’s stock.

A number of analysts recently weighed in on MNTA shares. Stifel Nicolaus reiterated a “hold” rating and issued a $15.00 price target (down from $22.00) on shares of Momenta Pharmaceuticals in a research report on Wednesday, October 4th. Zacks Investment Research downgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Barclays PLC reiterated an “equal weight” rating and issued a $16.00 price target (down from $17.00) on shares of Momenta Pharmaceuticals in a research report on Wednesday, October 4th. Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $14.00 price target (down from $18.00) on shares of Momenta Pharmaceuticals in a research report on Thursday, October 5th. Finally, Maxim Group set a $6.00 target price on shares of Momenta Pharmaceuticals and gave the stock a “sell” rating in a report on Thursday, August 3rd. Three research analysts have rated the stock with a sell rating and nine have given a hold rating to the stock. Momenta Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $15.00.

In other news, President Craig A. Wheeler sold 35,667 shares of the firm’s stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $19.03, for a total transaction of $678,743.01. Following the completion of the transaction, the president now directly owns 286,121 shares of the company’s stock, valued at approximately $5,444,882.63. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Craig A. Wheeler sold 4,116 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $15.07, for a total transaction of $62,028.12. Following the transaction, the president now directly owns 269,231 shares of the company’s stock, valued at $4,057,311.17. The disclosure for this sale can be found here. Insiders have sold a total of 64,372 shares of company stock valued at $1,146,002 over the last ninety days. Company insiders own 4.40% of the company’s stock.

Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) opened at $12.65 on Wednesday. Momenta Pharmaceuticals, Inc. has a fifty-two week low of $11.85 and a fifty-two week high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.03. The company had revenue of $24.09 million during the quarter, compared to analysts’ expectations of $29.58 million. Momenta Pharmaceuticals had a negative net margin of 55.61% and a negative return on equity of 16.20%. The business’s quarterly revenue was down 17.3% on a year-over-year basis. During the same period last year, the business earned ($0.26) EPS. sell-side analysts anticipate that Momenta Pharmaceuticals, Inc. will post -1.16 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “The Manufacturers Life Insurance Company Grows Holdings in Momenta Pharmaceuticals, Inc. (MNTA)” was first posted by Stock Observer and is owned by of Stock Observer. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.thestockobserver.com/2017/11/15/the-manufacturers-life-insurance-company-grows-holdings-in-momenta-pharmaceuticals-inc-mnta.html.

Momenta Pharmaceuticals Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Want to see what other hedge funds are holding MNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply